- Home
- CUE vs SNAL Comparison
CUE vs SNAL Comparison
Compare CUE & SNAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CUE | SNAL |
|---|---|---|
| Founded | 2014 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.6M | 19.3M |
| IPO Year | 2017 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CUE | SNAL |
|---|---|---|
| Price | $0.62 | $0.76 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | 19.4M | ★ 32.9M |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 61.11 | ★ 120.00 |
| EPS | ★ N/A | N/A |
| Revenue | $27,466,000.00 | ★ $81,225,622.00 |
| Revenue This Year | N/A | $15.53 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 195.75 | N/A |
| 52 Week Low | $0.17 | $0.34 |
| 52 Week High | $1.03 | $2.16 |
Technical Indicators
Market Signals| Indicator | CUE | SNAL |
|---|---|---|
| Relative Strength Index (RSI) | 72.18 | 52.00 |
| Support Level | $0.24 | $0.53 |
| Resistance Level | $0.66 | $0.89 |
| Average True Range (ATR) | 0.11 | 0.18 |
| MACD | 0.05 | 0.06 |
| Stochastic Oscillator | 70.92 | 22.83 |
Price Performance
Historical ComparisonAbout CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About SNAL Snail Inc.
Snail Inc is an independent developer and publisher of interactive digital entertainment for consumers around the world, with a portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States. The Company has one operating and reportable segment. The company operates in the USA, the UK and Other Countries.